583 results about "Albumin" patented technology

The invention belongs to the technical field of biological detection, and discloses a kit and a method for quantitatively detecting residual quantity of host cell protein of pichia pastoris in order to solve the problems of limit of quantitation and low detection sensitivity of an existing detection method. According to the present invention, the empty plasmid without the recombinant human serum albumin gene is introduced into the pichia pastoris, and purification is performed by combining the Protein A chromatographic column and the host cell protein coupling affinity column, such that the prepared polyclonal antibody can be effectively used for the quantitative detection of the residual amount of the pichia pastoris host cell protein in the biological product; the kit formed by the polyclonal antibody has good accuracy and repeatability on the quantitative detection of the host cell protein residues in the pichia pastoris source biological products, the quantification limit is 0.2 ng / mL, and the kit provided by the invention can meet the quantitative detection of the host cell protein residues in all the pichia pastoris source biological products.

A pharmaceutical composition comprises a GPCR agonist fusion protein in which a GPCR agonist peptide is covalently coupled to albumin via a linker in a manner that is resistant to a retro-Michael addition. Advantageously, compositions presented herein avoid decoupling of the agonist form the albumin while retaining the agonist in a steric relationship to the albumin that allows for effective binding and activation of the GPCR while also enabling gp60-mediated transcytosis and FcRn-mediated albumin recycling. These properties enable ultra-low dosages for the GPCR agonist fusion protein to give a therapeutic effect while substantially reducing or even entirely avoiding adverse effects otherwise commonly associated with unbound agonists. Such retro-Michael resistant composition is generally achieved by conformational modification of the albumin, resulting in stereoselective coupling of the linker to the albumin.

A pharmaceutical composition comprises a GPCR agonist fusion protein wherein the GPCR agonist peptide is covalently conjugated to an albumin via a linker in a manner that is resistant to a reverse Michael addition. Advantageously, the compositions presented herein avoid uncoupling of the agonist to the albumin while maintaining the agonist and the albumin in a spatial relationship that allows efficient binding and activation of the GPCR while also enabling gp60-mediated endocytosis transport and FcRn-mediated albumin recirculation. These characteristics enable ultra-low doses of GPCR agonist fusion proteins to produce therapeutic effects while significantly reducing or even completely avoiding side effects that would otherwise be typically associated with unbound agonists. Such reverse Michael resistant compositions are typically achieved by conformationally modifying an albumin, resulting in a stereoselective coupling of a linker to the albumin.

The invention discloses a highly inert Gd-DOTA-based contrast agent with a hydrophobic side chain as well as a preparation method and application of the highly inert Gd-DOTA-based contrast agent, and two novel Gd-DOTA-based contrast agents Gd-L1 and Gd-L2 are successfully developed by respectively connecting hydrophobic 3-phenyl propylamine and 3, 3-diphenyl propylamine to Gd-DOTABA. The two novel Gd-DOTA-based contrast agents remarkably improve the chemical inertness of the complex, the dissociation half-life period of the complex in a 1 M HCl solution at 37 DEG C is about 5 times that of Gd-DOTA, and a powerful guarantee is provided for clinical safety; the MRI (Magnetic Resonance Imaging) performance of the liver in a mouse shows that Gd-L1 is equivalent to commercially available Gd-BOPTA and is suitable for imaging of a liver and gall system; after the Gd-L2 is combined with the human serum albumin, the longitudinal relaxation rate is obviously increased (r1 = 14.8 mM <-1 > s <-1 >, 1.4 T, 37 DEG C), the blood elimination half-life period in a rabbit model is about 18 minutes, and the Gd-L2 is suitable for vascular MRI (Magnetic Resonance Imaging). The two contrast agents avoid the spleen residual problem, the organ accumulation possibility is reduced, and a safer and more efficient MRI diagnostic tool is provided for clinic.

The invention provides a postoperative bleeding risk monitoring method and system for a hepatobiliary patient. The method comprises the following steps: collecting real-time multi-modal data; constructing an LSTM-CNN hybrid model by using the time-frequency decomposition features, and obtaining a local tissue hypoxia index and a vasomotor function anomaly probability; the low-frequency impedance change rate and the albumin level are fused through a random forest algorithm, and the ascites occurrence probability and the effusion amount predicted value are obtained; and generating a bleeding point positioning coordinate and a thermodynamic diagram risk grade. And calculating a comprehensive bleeding risk probability and positioning a bleeding area. And generating graded early warning signals and recommending personalized treatment schemes or nursing suggestions. According to the invention, the LSTM-CNN hybrid model, the random forest algorithm and the three-dimensional convolutional neural network are adopted to deeply extract different data features, so that the limitation of single index evaluation is avoided. A causal relationship model is established through the Bayesian network, and the comprehensive risk probability calculation preciseness is improved; the early warning threshold is dynamically adjusted by combining the individual characteristics of the patient, and the traditional problem of easy misjudgment is solved.

1. The name of the design product: packaging box (Baiyisheng Liao-Shen composite albumin peptide). 2. The use of the design product: used for the outer packaging box of articles. 3. The design points of the design product: in the combination of shape and pattern. 4. The picture or photo that best indicates the design points: perspective view 1.

A pharmaceutical composition comprises a GPCR agonist fusion protein in which a GPCR agonist peptide is covalently coupled to albumin via a linker in a manner that is resistant to a retro-Michael addition. Advantageously, compositions presented herein avoid decoupling of the agonist form the albumin while retaining the agonist in a steric relationship to the albumin that allows for effective binding and activation of the GPCR while also enabling gp60-mediated transcytosis and FcRn-mediated albumin recycling. These properties enable ultra-low dosages for the GPCR agonist fusion protein to give a therapeutic effect while substantially reducing or even entirely avoiding adverse effects otherwise commonly associated with unbound agonists. Moreover, these properties also enable transport of the GPCR agonist fusion protein across the blood brain barrier and therefore allow treatment of neural disorders.

The invention provides application of a product of targeted Vasorin protein in preparation of a product for diagnosing or treating kidney diseases with reduced glucose tolerance, and belongs to the technical field of biological medicines. Vasorin is used as a biomarker of the hypoglucose tolerance nephropathy, the level of Vasorin in urine of a patient is absolutely quantified through an ELISA technology, and the Vasorin has great clinical value and practical significance in early discovery and intervention of the hypoglucose tolerance nephropathy. According to the present invention, the gene or the Vasorin protein for controlling the Vasorin expression is adopted as the target spot, and the specific vector is adopted to perform overexpression on the Vasorin protein, such that the lipid droplet deposition and the reactive oxygen species (ROS) overgeneration in the renal tubular epithelial cell can be effectively improved, and the albumin reabsorption ability of the renal tubular can be improved so as to effectively treat the glucose tolerance reduced nephropathy.

The application provides a preparation method of a functionalized phage probe and application of the functionalized phage probe in detection of escherichia coli. The functionalized phage is a recombinant phage (M13KO7@SaBP) in which streptavidin binding peptide (SaBP) is fused and expressed at the N terminal of the main capsid protein P8 protein of M13K07 phage. In the application, the gene encoding SaBP (MDVEAWLGAR) is inserted into the N terminal of the P8 protein gene of M13K07 phage by site-directed mutagenesis to prepare M13K07@SaBP. The stable signal amplification is realized by using the abundant P8 protein (about 2700) of M13 phage and the super strong binding force of biotin-streptavidin, the interference of food sample matrix is reduced by combining the magnetic separation technology, and a detection method of escherichia coli with high sensitivity and small sample matrix interference is constructed.

The invention relates to an aptamer specifically combined with beta-lactoglobulin and application of the aptamer, and belongs to the technical field of biological detection. According to the aptamer and the preparation method thereof, a binding domain base, participating in recognition, of the aptamer is predicted through molecular docking firstly, then the binding domain base is subjected to directional mutation, the aptamer with the recognition performance improved is obtained, the affinity of the aptamer to beta-lactoglobulin is 10.6 nM, and the aptamer has no recognition capacity on alpha-lactalbumin, casein, bovine serum albumin, immune globulin G, lactose and the like and can be used for preparing the aptamer with the recognition performance improved. Therefore, the aptamer disclosed by the invention has good sensitivity and specificity on the beta-lactoglobulin. On the basis, a fluorescence polarization method is directly constructed by utilizing the characteristic that the beta-lactoglobulin is a biomacromolecule, when the beta-lactoglobulin exists, an aptamer marked by a fluorophore FAM recognizes the beta-lactoglobulin to form an aptamer beta-lactoglobulin compound, and the fluorescence polarization value is relatively large, so that the beta-lactoglobulin compound can be used for identifying the beta-lactoglobulin. Therefore, the specific detection of the low-concentration beta-lactoglobulin is realized.

The invention discloses coagulation-promoting freeze-dried microspheres, a preparation method thereof and application of the coagulation-promoting freeze-dried microspheres in a vacuum blood collection tube, and belongs to the technical field of medical instruments. The coagulation-promoting freeze-dried microspheres comprise kaolin, coagulation-promoting powder, bovine serum albumin, a dispersing agent and an adhesive, the preparation method comprises the steps of raw material suspension preparation, liquid nitrogen drop bead freezing forming, vacuum freeze drying and microsphere screening. According to the preparation method, the coagulation accelerator is prepared into the form of the freeze-dried microspheres, so that the production process is simplified, the energy consumption is reduced, the biological activity of coagulation accelerating components is effectively protected, the coagulation accelerating effect is quicker, more stable and more uniform, and the product quality of the vacuum blood collection tube and the reliability of clinical examination results are remarkably improved.

The invention relates to a nano bismuth agent for preventing and / or treating gastritis infection as well as a preparation method and application thereof, the preparation method comprises the following steps: respectively dissolving soluble bismuth salt and a sulfur-containing compound, mixing, and reacting to obtain the nano bismuth agent after the reaction is finished, the sulfur-containing compound is any one or a combination of at least two of thioamino acid, vitamin B1, thioacetamide, sodium sulfide, sodium thiosulfate, bovine serum albumin, whey protein, ovalbumin or metallothionein. The prepared nano bismuth agent has efficient antibacterial performance, shows an excellent curative effect which is two orders of magnitude higher than that of an existing bismuth complex on clinically separated drug-resistant helicobacter pylori, and does not further induce increase of drug resistance of the helicobacter pylori.

The present disclosure relates to a process for obtaining sunflower protein isolates which encompasses the steps of shelling, cold pre-pressing, oil extraction, protein extraction and isolate purification. The process optimizes protein yield while employing mild processing conditions to maintain functionality. The obtained isolates exhibit high protein content, desirable emulsification capacity and water / oil retention, and neutral color characteristics, making them suitable for a variety of food applications. Thus, a sunflower globulin protein isolate, a sunflower albumin protein isolate and the use of the sunflower globulin protein isolate or sunflower albumin protein isolate in food products are also disclosed.

The invention provides a method for regulating and controlling growth and metabolism of caproic acid bacteria by using marine active peptides in a baijiu fermentation process. According to the method, the marine active peptides are added in an anaerobic fermentation stage of baijiu preparation to regulate and control the growth and metabolism of the caproic acid bacteria; wherein the marine active peptide is chlorella pyrenoidosa peptide, schizochytrium limacinum peptide, fish albumin peptide or euphausia superba peptide. According to the method, active peptides with specific sources are added into an anaerobic culture system, so that the growth of caproic acid bacteria can be promoted, energy metabolism can be enhanced, and the activity of key enzymes such as caproic acid dehydrogenase and caproic acid synthase can be activated, and therefore, the generation amount of flavor acids such as caproic acid and butyric acid can be increased, the fermentation quality can be improved, and the flavor level and esterification precursor substance content of Baijiu can be improved.

This invention discloses a method and sensor for adiponectin detection using a polyaniline and polyacrylic acid-modified wire mesh carbon electrode, relating to the field of adiponectin detection technology. The method involves electrochemically activating the wire mesh carbon electrode, electropolymerizing it to form a polyaniline-polyacrylic acid composite modification layer, immobilizing adiponectin monoclonal antibody after activation with N-hydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, blocking the antibody with bovine serum albumin, and reacting it with a serum sample. The adiponectin concentration is determined based on the peak potential shift and peak current change. This invention simultaneously achieves both conductive transport and antibody immobilization, reduces non-specific adsorption and serum interference, and improves detection sensitivity, repeatability, and quantitative accuracy.

The invention relates to the technical field of biomedicine nanotechnology, in particular to a high-stability engineered exosome based on rigid hydrophobic anchoring and micelle disassembly and purification as well as a preparation method and application of the high-stability engineered exosome. According to the invention, a ternary surface structure of rigid hydrophobic anchoring-hydrophilic polymer spacer arm-targeting ligand (L-S-T) is constructed, cholesterol hemisuccinate or multi-branched lipid is selected as an anchoring group, and the problem that conventional phospholipid modification is easy to fall off in vivo and in an albumin-containing preparation is obviously solved; a technology of'micellar insertion after temperature control 'combined with'CMC critical concentration adjustment and purification' is adopted, lossless insertion of functional molecules is realized by utilizing thermodynamic driving force, and residual micelles are induced to be disintegrated into monomers by adjusting the concentration of a system to be lower than the concentration of critical micelles, so that efficient removal of free impurities is realized through conventional ultrafiltration. The engineered exosome has the advantages of long circulation, high targeting and excellent storage stability, and has important clinical application and commercial transformation prospects.

The invention provides an organoid membrane protein and intracellular protein immunofluorescence in-situ co-staining method, which comprises the following steps of: sealing and fixing organoid glue drops, adding a mixed solution of membrane protein primary antibody and a Dune phosphate buffer solution containing bovine serum albumin for incubation, performing membrane permeation by using a permeation agent, sealing and washing, and drying to obtain the organoid membrane protein and intracellular protein immunofluorescence in-situ co-staining product. Adding a mixed solution of an intracellular protein primary antibody and a Dune phosphate buffer solution containing bovine serum albumin into the cell plate where the transparent organ-like glue drops are located, incubating and washing, then adding a mixed solution of a membrane protein and a fluorescent secondary antibody of the corresponding species of the intracellular protein, incubating and washing in a dark place, and finally obtaining the membrane protein / intracellular protein fluorescent antibody. And finally, adding a mixed solution of DAPI and a Duncheng phosphate buffer solution, and incubating and washing in a dark place again to obtain the membrane protein and intracellular protein immunofluorescence in-situ co-dyed organoid. According to the method, high-quality and high-fidelity membrane protein and intracellular protein in-situ co-dyeing is successfully realized, the integrity of a three-dimensional structure and the high efficiency of an experimental process are taken into consideration, and the method is convenient to operate, high in repeatability and good in universality.

The invention provides an extraction method of coconut globulin, and relates to the technical field of coconut protein extraction. The method for extracting the coconut globulin comprises the following steps: removing albumin from defatted coconut powder by using distilled water, performing nitrogen pressure-boosting drying, mixing with a NaCl solution with relatively low concentration, performing high-voltage pulse electric field circulation treatment, stirring and extracting the NaCl solution, freeze-drying, redissolving, dialyzing and purifying to obtain the coconut globulin. According to the method, the defects in the prior art are overcome, and the extraction rate of the coconut globulin and the purity of the final product are improved while the good stability and emulsibility of the coconut globulin are ensured.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke. By constructing a mouse model of heatstroke-induced myocardial injury and observing indicators such as rectal temperature, blood routine tests, blood biochemistry, oxidative stress, and cardiac function, this invention found that lemon balm glycosides can significantly reduce the increase in rectal temperature caused by heatstroke in mice, increase the content of red blood cells and albumin in plasma, and reduce the level of oxidative stress in myocardial cells. Therefore, the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke is proposed.

The present invention relates to MSLN-specific binding constructs comprising a designed ankyrin repeat domain with binding specificity for MSLN and a chelator capable of bonding to a radionuclide, as well as to such MSLN-specific binding constructs comprising a half-life extending moiety with binding specificity for serum albumin. The invention further relates to methods of producing such radio-labelled MSLN-specific binding constructs, pharmaceutical compositions comprising such constructs, and the use of such constructs or pharmaceutical compositions in methods for treating, imaging or diagnosing diseases, such as cancer.

To provide compositions and methods for increasing the stability of recombinant nanobodies. Also provided are recombinant Nanobodies comprising an IL-2 polypeptide that binds serum albumin, and uses thereof for treating cancer.SOLUTION: There is provided a recombinant Nanobody comprising a human serum albumin (HSA) binding polypeptide and an IL-2 polypeptide, wherein the HSA binding polypeptide specifically binds to an HSA epitope selected from the group consisting of epitope 1, epitope 2, epitope 3 and epitope 4.SELECTED DRAWING: Figure 16

A clinical decision support device, comprising: a parameter acquisition module, configured to acquire measured values for markers in a biomarker combination of a subject, wherein the biomarker combination at least comprises an alpha fetoprotein, an abnormal prothrombin, γ-glutamyltransferase, and an albumin; a risk assessment module, configured to input the measured values for the markers in the biomarker combination into a calculation model to obtain an output of the calculation model as a liver cancer risk prediction result of the subject; and an output module, configured to output the liver cancer risk prediction result of the subject. Also disclosed are a sample analysis system and a method for assessing a liver cancer risk of a subject, capable of better assessing a liver cancer risk of a subject.

Disclosed are: an albumin-binding prodrug that can stably and selectively bind to albumin capable of targeting cancer while also stably binding to drugs; an albumin-drug conjugate in which the albumin-binding prodrug is bound to albumin; a method for preparing the albumin-drug conjugate; and a pharmaceutical composition for preventing or treating cancer, comprising the albumin-binding prodrug or the albumin-drug conjugate.

The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and / or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

The invention discloses a fuzzy intelligent control method and device for a pichia pastoris fermentation process. The fuzzy intelligent control method comprises the following steps: (1) integrating an online sensor in a bioreactor and monitoring state parameters of fermentation liquor in real time; (2) inputting the monitored parameters into a central control system, and processing the parameters through a fuzzy intelligent control algorithm; and (3) according to an output instruction of the fuzzy intelligent control algorithm, cooperatively regulating and controlling fermentation operation parameters in real time. According to the method disclosed by the invention, a fuzzy intelligent control algorithm is developed by monitoring dissolved oxygen, relative concentration of dissolved carbon dioxide, methanol concentration and pH in fermentation liquor in the fermentation process in real time, so that the fermentation process is accurately regulated and controlled by multi-parameter coordination, and the method is applied to process regulation and control of pichia pastoris fermentation expression recombinant protein. The expression quantity and the production efficiency of the recombinant albumin can be remarkably improved, the production period is shortened, and the method is suitable for industrial large-scale production.

The application discloses an albumin nano-drug based on HSP90 inhibitor and a preparation method and application thereof, and belongs to the technical field of medicines.The short peptide A6 is modified to human blood albumin through a connecting chain, and the human blood albumin modified by the A6 is self-assembled with geldanamycin derivative G2111 in the presence of an organic solvent, so that the G2111 is combined to the hydrophobic region of the human blood albumin through a non-covalent bond, effective loading of the G2111 is realized, the solubility of the geldanamycin derivative is improved, the drug is targetedly released into cancer cells with high expression of CD44, the targeted accumulation of the drug in tumor tissues is enhanced, damage to other normal tissues and cells caused by off-target effects of the drug is avoided, the albumin nano-drug can be simultaneously used for chemotherapy of leukemia and solid tumors, and has important practical significance.

The application belongs to the technical field of nanomedicine, tumor treatment and immunotherapy, and specifically provides a copper death selective induction nanoparticle targeting tumor mitochondria, which is prepared by the following preparation method: S1, TPY is specifically coupled with MHI through a condensation reaction to obtain MTPY; S2, MTPY is complexed with copper ions to obtain an MTPY-Cu complex; and S3, the MTPY-Cu complex is self-assembled with albumin to form an MTPY-Cu@Alb nanoparticle. The copper dose of the application is only 1 / 1000 of that of free Cu 2+ , and the equivalent immune regulation and killing effects can be achieved; the primary tumor and distant tumor foci can be inhibited, and lung metastasis can be reduced; and the application can induce immune memory and prevent recurrence; the application is combined with cisplatin to significantly enhance the therapeutic effect and reverse the induced immunosuppression; and the application has high biological safety, and has no obvious hepatorenal toxicity or hemolytic reaction.

The invention relates to the technical field of cell biology, in particular to an iNKT cell cryopreservation solution and a method for cryopreserving iNKT cells by using the cryopreservation solution. The invention provides an immune cell cryopreservation solution. The immune cell cryopreservation solution comprises human serum albumin, a basic low-temperature protection solution and an optional human platelet lysate. The immune cell freezing medium does not contain animal-derived components except for human bodies, and has the advantages of simple components and good stability. According to the cryopreservation liquid disclosed by the invention, through the combined action of the basic low-temperature protection liquid (such as CryoStor10 (CS10)) and the human serum albumin, the motility rate after cell recovery is improved, and the damage to immune cells (such as iNKT) in the cryopreservation process is reduced. After a small amount of human platelet lysate is further added, the survival rate of cell resuscitation and the amplification capacity can be further improved.

This invention discloses a NK cell culture kit, its culture method, and its application. The kit includes an amplification medium, a high-efficiency induction medium, an NK-A coating solution, an NK-B mixture, and an NK-C mixture. The amplification medium contains basal medium, NAD+, human serum albumin, transferrin, β-glucan, glutathione, β-mercaptoethanol, and linoleic acid. The high-efficiency induction medium, in addition to the amplification medium components, contains soybean peptides, nicotinamide, inulin, and N-acetyl-L-cysteine. The NK-A coating solution contains heparin sodium, monoclonal antibodies, and antibodies. The NK-B mixture contains Inbakicept, IL-2, and IL-15. The NK-C mixture contains linolenic acid, IL-2, and IL-18. The Inbakicept factor in the kit can activate NK cells and enhance their cytotoxicity; linolenic acid can inhibit T cell proliferation, increase NK cell purity, and enhance cell efficacy.

The invention discloses a mineralization repair type oral cavity and throat nursing material for middle-aged and elderly people and a preparation method thereof. The nursing material consists of a core mineralization precursor, a function relieving component and an auxiliary synergistic component, wherein the core mineralization precursor is a biocompatible mineralization matrix of modified hydroxyapatite loaded carbon nitride quantum dots, and is used for realizing mucous membrane mineralization repair; the functional soothing component is a mixture of dihydromyricetin, a licorice extract and a menthol-beta-cyclodextrin inclusion compound, and has mild soothing and anti-inflammatory effects; the auxiliary synergistic component is a mixture of bovine serum albumin and a gamma-polyglutamic acid-g-methoxypolyethylene glycol derivative, and a mineralized precursor is stabilized and mucous membrane adhesion is enhanced by constructing a protein nanocage structure. By optimizing the process, the production efficiency and stability are improved, the biological safety is enhanced, the nursing requirements of middle-aged and elderly oral cavity and throat sensitive mucous membranes are better met, and the oral cavity and throat sensitive mucous membrane repairing gel is suitable for oral cavity mucous membrane sensitive repairing and chronic pharyngitis auxiliary nursing.